About KEYMED BIO-B Company

Conoa Biomedical Technology Co., Ltd. is a biotechnology company with multiple clinical-stage assets, each of which is a strong competitor in its respective competitive field. We focus on independently discovering and developing innovative biotherapeutics to meet a large number of unmet medical needs in the fields of autoimmunity and oncology treatment. With a strong foundation in biomedical research, we have mastered in-house drug discovery and development techniques, including the technologies that make up our innovative antibody discovery platform and our own novel T-cell redirection (NTCe) bispecific antibody platform. In less than five years since our establishment, we have consistently explored the extremely challenging field of disease treatment, which is in short supply. We now have more than ten drug candidates in in-house development, five of which are in the clinical phase. Our own products, which are currently under development, apply cutting-edge scientific discoveries and reflect our deep market insight. Driven by economic growth and health-care system reforms, health-care spending increased significantly in the first two decades of the new millennium. Due to rapid urbanization, changes in residents' lifestyles, and environmental changes, China's epidemiological focus is shifting from the prevalence of infectious diseases to the prevalence of cancer and other chronic diseases. These basic and evolving trends present new challenges to public health and reveal new areas of disease that place a heavy burden on society due to inadequate treatment options. To support our innovative biopharmaceutical research and development work, we have established a fully integrated platform covering all key functions of biopharmaceutical development, including target verification, lead compound generation and optimization, pre-clinical evaluation, process development, translational research, clinical development and production. This integrated platform allows us to quickly and cost-effectively discover, build, expand and advance our diverse pipeline of innovative and differentiated antibody therapeutics, including monoclonal antibodies, antibody conjugates, and bispecific antibodies.